Chelsea McLean
Impact in
-
- Cancer Genomics and Diagnostics
-
- Cancer Cells and Metastasis
Papers in
-
- Viral Infections and Outbreaks Research 8
-
- Epigenetics and DNA Methylation 5
- Histone Deacetylase Inhibitors Research 2
- Ubiquitin and proteasome pathways 1
- Protein Degradation and Inhibitors 1
- Co-authors
- Fred van Leeuwen (3 shared papers)Ino D. Karemaker (1 shared paper)Emile E. Voest (5 shared papers)Kristian Helin (2 shared papers)Paul D. Soloway (2 shared papers)Salo Ooft (2 shared papers)Diego Pasini (1 shared paper)Anders M. Lindroth (1 shared paper)
- Journals
- The FASEB Journal (2 papers)Nature Communications (1 paper)The Lancet Infectious Diseases (1 paper)npj Vaccines (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- NetherlandsBelgiumUnited States
In The Last Decade
Chelsea McLean
20 papers receiving 580 citations
Peers
Comparison fields: 5 of 76
- Cancer Research 87
- Oncology 132
- Molecular Biology 328
- Infectious Diseases 46
- Immunology 53
Countries citing papers authored by Chelsea McLean
This map shows the geographic impact of Chelsea McLean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chelsea McLean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chelsea McLean more than expected).
Fields of papers citing papers by Chelsea McLean
This network shows the impact of papers produced by Chelsea McLean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chelsea McLean. The network helps show where Chelsea McLean may publish in the future.
Co-authors
The 25 scholars most cited alongside Chelsea McLean, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 99 | |
| 2 | 2008 | 99 | |
| 3 | 2021 | 93 | |
| 4 | 2020 | 69 | |
| 5 | 2015 | 36 | |
| 6 | 2020 | 35 | |
| 7 | 2019 | 33 | |
| 8 | 2019 | 29 | |
| 9 | 2017 | 27 | |
| 10 | 2022 | 22 | |
| 11 | 2023 | 8 | |
| 12 | 2023 | 8 | |
| 13 | 2024 | 7 | |
| 14 | 2009 | 6 | |
| 15 | 2024 | 4 | |
| 16 | 2023 | 3 | |
| 17 | 2023 | 2 | |
| 18 | 2016 | 2 | |
| 19 | 2016 | 2 | |
| 20 | 2025 | 1 |
About Chelsea McLean
Chelsea McLean is a scholar working on Infectious Diseases, Molecular Biology, Oncology, Epidemiology and Pediatrics, Perinatology and Child Health, having authored 22 papers that have together received 586 indexed citations. Recurring topics across this work include Viral Infections and Outbreaks Research (8 papers), Epigenetics and DNA Methylation (5 papers), Hepatitis B Virus Studies (4 papers), Histone Deacetylase Inhibitors Research (2 papers), Obesity, Physical Activity, Diet (1 paper), Ubiquitin and proteasome pathways (1 paper), Cutaneous Melanoma Detection and Management (1 paper) and Protein Degradation and Inhibitors (1 paper). The work is most often cited by research in Cancer Research (87 citations), Oncology (132 citations), Molecular Biology (328 citations), Infectious Diseases (46 citations) and Immunology (53 citations). Chelsea McLean has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include Fred van Leeuwen, Ino D. Karemaker, Emile E. Voest, Kristian Helin, Paul D. Soloway, Salo Ooft, Diego Pasini, Anders M. Lindroth, Gregoriy A. Dokshin and Jenna Persson. Their work appears in journals such as The FASEB Journal, Nature Communications, The Lancet Infectious Diseases, npj Vaccines and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.